Checkmate_CMP-001-010 (Melanoma)

What is the Purpose of this Study?

The study has two parts: a screening period and a study dosing period.

If you choose to join the study during the screening period, you will:
- Have physical exams and blood draws
- Have imaging done (CT, MRI, photographs)
- Have a tumor biopsy done

During the study dosing period, you will:
- Receive the study drug(s) directly into your skin/tumor or through an IV
- Return for a follow-up visit 100 days after the last study drug injection
- Have phone calls every 3 months after you finish the study treatment
What is the Condition Being Studied?
Checkmate_CMP-001-010 (Melanoma)

Who Can Participate in this Study?

People who:

- Have received, or are currently receiving, any anti-PD-1 either alone or in combination with other drugs for advanced melanoma, and the cancer has progressed, despite treatment.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out how an experimental drug called CMP-001 works with nivolumab in your body and against your cancer.

Study Details

Full Title
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination with Intravenous Nivolumab in Subjects with Refractory Unresectable or Metastatic Melanoma
Principal Investigator

Protocol Number
IRB:
PRO00106865

NCT:
NCT04698187
ClinicalTrials.gov
View on ClinicalTrials.gov